SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01604122

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Cross-sectional, Non-interventional Burden Of Disease (Bod) Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (Ttr-fap) Or Transthyretin Cardiomyopathy (ttr-cm) And Caregivers

This study is an online (web-based) or paper-based survey for patients with transthyretin familial amyloidosis polyneuropathy (TTR-FAP) and caregivers. The results will be used to describe the emotional, physical, and financial impact of having TTR-FAP or caring for someone who has the disease.

NCT01604122 Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) Transthyretin Cardiomyopathy (TTR-CM) Familial Amyloid Cardiomyopathy Senile Systemic Amyloidosis (SSA)
MeSH:Polyneuropathies Amyloid Neuropathies Cardiomyopathies Amyloidosis, Familial Amyloidosis
HPO:Amyloidosis Cardiomyopathy Motor polyneuropathy Polyneuropathy

2 Interventions

Name: No drug

Description: No drug.
Type: Other
Group Labels: 1

Patients

Name: No drug

Description: No drug.
Type: Other
Group Labels: 1

Caregivers


Primary Outcomes

Description: Main characteristics included were education level and employment status which were asked from all participants and caregivers. Type of job (full-time, part-time) was asked only from those participants and caregivers who provided their employment status as employed. Those who were unemployed reported their cause of unemployment, whether it was due to ATTR or not.

Measure: Demographical Characteristics of Participants

Time: Baseline (Day 1)

Description: Duration of disease was defined as the time from diagnosis of disease until baseline visit. This outcome measure was planned to be assessed for reporting arm of participants diagnosed with ATTR.

Measure: Disease Characteristics of Participants: Disease Duration

Time: Baseline (Day 1)

Description: Genetic mutation leads to misfolding of protein transthyretin (TTR) which results in ATTR. In this outcome, number of participants with each type of resulted mutation type (Val30Met, wild type TTR, Phe64Leu, Ser77Tyr, Thr60Ala or other than these) were reported. This outcome was planned to be assessed for reporting arm of participants diagnosed with ATTR.

Measure: Disease Characteristics of Participants: Mutation Type

Time: Baseline (Day 1)

Description: TTR protein is primarily synthesized in the liver. Liver transplantation was considered as one of the measure to eliminate the main source of variant TTR. In the study, participants who were diagnosed with ATTR were asked for their liver transplantation status (whether they had transplantation or not). In this outcome measure, number of participants with liver transplant status were reported. This outcome was planned to be assessed for reporting arm of participants diagnosed with ATTR.

Measure: Disease Characteristics of Participants: Liver Transplantation Status

Time: Baseline (Day 1)

Description: Family history of participants diagnosed with ATTR was assessed to determine whether family history of ATTR was a significant risk factor for ATTR or not. This outcome was planned to be assessed for reporting arm of participants diagnosed with ATTR.

Measure: Disease Characteristics of Participants: Number of Participants With Family History of ATTR

Time: Baseline (Day 1)

Description: Mobility, i.e., ability to walk was assessed as a part of loss of functioning in the participants diagnosed with ATTR. In this outcome, number of participants with their different mobility status along with the use of mobility aids (able to walk normally, some problems with feet but able to walk without difficulty, some difficulty walking but can walk without help, confined to bed all the time, need 1 cane or crutch to walk, need 2 canes/crutches or a walker to walk) were reported.

Measure: Disease Characteristics of Participants: Mobility Status

Time: Baseline (Day 1)

Description: SF-12 was a patient reported outcome survey that represented overall health status by measuring 8 health-related aspects of an individual: Body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Responses on the SF-12 were also used to calculate 2 summary scores: Physical component score (PCS) and mental component score (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), where 100 indicated good health condition.

Measure: 12-Item Short-Form Health Survey (SF-12) Scores

Time: Baseline (Day 1)

Description: HADS: participant rated 14-item questionnaire with 2 subscales; HADS-anxiety scale (HADS-A) and HADS-depression scale (HADS-D). HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for each subscale; higher score indicating greater severity of anxiety and depression symptoms.

Measure: Hospital Anxiety and Depression Scale (HADS): Depression and Anxiety Subscale Scores

Time: Baseline (Day 1)

Description: EQ-5D-3L: participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total score range of 0.05 to 1.00; higher scores indicating a better health state.

Measure: Euro Quality of Life (EQ-5D-3L)- Health State Profile Utility Score

Time: Baseline (Day 1)

Description: EQ-5D: participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.

Measure: Euro Quality of Life (EQ-5D-3L)- Visual Analog Scale (VAS) Score

Time: Baseline (Day 1)

Description: The WPAI assesses work productivity and impairment. It was a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days prior to baseline visit. The questionnaire asked about current employment status, hours worked, hours missed from work and degree to which a specified health problem (ATTR) or caregiving affected work productivity and regular activities. Percentage of work time missed of participants were recorded and reported.

Measure: Work Productivity and Activity Impairment- Specific Health Version (WPAI-SH): Percent of Work Time Missed

Time: Baseline (Day 1)

Description: The WPAI assesses work productivity and impairment. It was a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days prior to baseline visit. The questionnaire asks about current employment status, hours worked, hours missed from work and degree to which a specified health problem (ATTR) or caregiving affected work productivity and regular activities. Component scores included percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. The computed percentage range for each sub-scale was from 0-100, where higher numbers indicating greater impairment and less productivity.

Measure: Work Productivity and Activity Impairment- Specific Health Version: Percent Impairment While Working

Time: Baseline (Day 1)

Description: The WPAI assesses work productivity and impairment. It was a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days prior to baseline visit. The questionnaire asked about current employment status, hours worked, hours missed from work and degree to which a specified health problem (ATTR) or caregiving affected work productivity and regular activities. Component scores included percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. The computed percentage range for each sub-scale was from 0-100, where higher numbers indicating greater impairment and less productivity.

Measure: Work Productivity and Activity Impairment- Specific Health Version: Percent Overall Work Impairment

Time: Baseline (Day 1)

Description: The WPAI assesses work productivity and impairment. It was a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days prior to baseline visit. The questionnaire asks about current employment status, hours worked, hours missed from work and degree to which a specified health problem (ATTR) or caregiving affected work productivity and regular activities. Component scores included percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. The computed percentage range for each sub-scale was from 0-100, where higher numbers indicating greater impairment and less productivity.

Measure: Work Productivity and Activity Impairment- Specific Health Version: Percent Activity Impairment

Time: Baseline (Day 1)

Description: Healthcare resources use survey of participants diagnosed with ATTR and caregivers was assessed by questions concerning a variety of different types of treatment and resources including outpatient visits to healthcare providers, hospitalizations, emergency/urgent care visits, symptomatic treatments, and out-of-pocket costs (for example, costs of travel to receive care).

Measure: Healthcare Resource Use Survey: Number of Outpatient Visits to Healthcare Providers

Time: Baseline (Day 1)

Description: Healthcare resources use survey of participants diagnosed with ATTR and caregivers was assessed by questions concerning a variety of different types of treatment and resources including outpatient visits to healthcare providers, hospitalizations, emergency/urgent care visits, symptomatic treatments, and out-of-pocket costs (for example, costs of travel to receive care).

Measure: Healthcare Resource Use Survey: Number of Hospitalizations

Time: Baseline (Day 1)

Description: Healthcare resources use survey of participants diagnosed with ATTR and caregivers was assessed by questions concerning a variety of different types of treatment and resources including outpatient visits to healthcare providers, hospitalizations, emergency/urgent care visits, symptomatic treatments, and out-of-pocket costs (for example, costs of travel to receive care).

Measure: Healthcare Resource Use Survey: Number of Emergency Care Visits

Time: Baseline (Day 1)

Description: Healthcare resources use survey of participants diagnosed with ATTR was assessed by questions concerning a variety of treatments and resources included outpatient visits to healthcare providers, hospitalizations, emergency/urgent care visits, symptomatic treatments, and out-of-pocket costs. Number of participants (diagnosed with ATTR) who visited non-medical practitioners (nutrition consultant/dietician, chiropractor, acupuncturist, massage therapist, occupational therapist or other than these) for symptomatic treatments were reported.

Measure: Healthcare and Resource Use Survey: Symptomatic Treatment of Participants

Time: Baseline (Day 1)

Description: Healthcare resources use survey of participants diagnosed with ATTR was assessed by questions concerning a variety of treatments and resources included outpatient visits to healthcare providers, hospitalizations, emergency/urgent care visits, symptomatic treatments, and out-of-pocket costs. Number of visits of participants (diagnosed with ATTR) who visited non-medical practitioners (nutrition consultant/dietician, chiropractor, acupuncturist, massage therapist, occupational therapist or other than these) for symptomatic treatments were reported.

Measure: Healthcare Resource Use Survey: Number of Symptomatic Treatment Visits

Time: Baseline (Day 1)

Description: Healthcare resources use survey of participants diagnosed with ATTR was assessed by questions concerning a variety of treatments and resources included outpatient visits to healthcare providers, hospitalizations, emergency/urgent care visits, symptomatic treatments, and out-of-pocket costs (expenditure on nutritional supplements, non-prescription medications and travel to receive medical care).

Measure: Healthcare Resource Use Survey: Out-of-Pocket Costs

Time: Baseline (Day 1)

Description: Participants diagnosed with ATTR rated their pain due to the health condition based on 3 items: pain right now, average pain in the past week, and worst pain in the past week prior to baseline visit. All 3 items were rated on an 11-point numeric rating scale ranging from 0=none to 10=severe pain, where higher scores indicated severe pain.

Measure: Participants Pain Score

Time: Baseline (Day 1)

Description: Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of neuropathy on the quality of life of participants diagnosed with ATTR. Scoring was based on 35 questions that yield a TQOL as well as 5 subscale scores: activities of daily living, large fiber neuropathy/physical functioning, small fiber neuropathy, autonomic neuropathy, and symptoms. TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life. This outcome measure was planned to be analyzed only for the reporting arm of participants diagnosed with ATTR.

Measure: Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL): Total Scores

Time: Baseline (Day 1)

Description: Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of neuropathy on the quality of life of participants diagnosed with ATTR. It was summarized in 5 domains: (1) Activities of daily living (score ranges from 0 to 20, where higher score=worse quality of life); (2) Large fiber neuropathy/physical functioning (score ranges from -2 to 58, where higher score=worse condition); (3) Small fiber neuropathy (score ranges from 0 to 16, where higher score=worse condition); (4) Autonomic neuropathy (score ranges from 0 to 12, where higher score=worse condition) and (5) Symptoms (score ranges from 0 to 32, where higher score=less symptoms of disease). Total possible score range= -2 to 138, where higher score=worse quality of life. This outcome measure was analyzed only for the participants diagnosed with ATTR.

Measure: Norfolk Quality of Life-Diabetic Neuropathy Total Quality of Life: Subscale Scores

Time: Baseline (Day 1)

Description: KCCQ was a 23-item participant-completed questionnaire that assessed health status and health-related quality of life (HRQoL) in participants with heart failure. It was quantified in to following 10 summary scores: physical limitation, symptom frequency, symptom severity, and symptom stability, total symptoms, quality of life, social interference, self-efficacy, overall summary and clinical summary. Each summary score was scaled to range from 0 (minimum) to 100 (maximum), with higher scores representing greater disability. Total score ranged from 0 to 100, where higher scores indicated better functioning, fewer symptoms, and better disease specific quality of life.

Measure: Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores

Time: Baseline (Day 1)

Description: ZBI was a 22-item questionnaire designed to evaluate five broad aspects of caregiver burden in terms of personal and role strain associated with caregiving. Five broad aspects were: burden in the relationship, emotional well-being, social and family life, finances, loss of control over one's life. Each item rated on a 5 point scale anchored at 0 for "never" and 4 for "nearly always." Total score ranges from 0-88 with higher scores indicating increased burden of care.

Measure: Zarit Burden Interview (ZBI): Total Scores

Time: Baseline (Day 1)

Description: A questionnaire designed to evaluate aspects of caregiver burden in terms of personal and role strain associated with caregiving. Total score of ZBI scale ranges from 0-88 with higher scores indicating increased burden of care. Five subscale scores were also calculated: (1) Burden in the relationship (consist of 6-items, ranging from 0 to 24 where higher scores indicating increased burden in relationship); (2) Emotional well-being (consisting of 7-items, ranging from 0 to 28 where higher scores indicating worse condition; (3) Social and family life (consisting of 4-items, ranging from 0 to 16 where higher scores indicating worse life condition); (4) Finances (consisting of a single item, scored from 0 to 4 where higher scores indicating worse financial condition); and (5) Loss of control over one's life (consisting of 4-items, ranging from 0 to 16 where higher scores indicating worse control over life).

Measure: Zarit Burden Interview: Subscale Scores

Time: Baseline (Day 1)

Description: Caregivers completed a series of questions related to the number of hours per week spent on providing care and support to the participants diagnosed with ATTR.

Measure: Caregiver Burden Items Assessment: Number of Hours Per Week Spent in Care of the Participants With ATTR

Time: Baseline (Day 1)

Description: Caregivers completed a series of questions related to the loss in their working time while providing care and support to the participants diagnosed with ATTR.

Measure: Caregiver Burden Items Assessment: Work Time Lost

Time: Baseline (Day 1)

Description: Caregivers completed a series of questions related to the total cost spent on providing healthcare support to participants diagnosed with ATTR.

Measure: Caregiver Burden Items Assessment: Total Cost

Time: Baseline (Day 1)

Time Perspective: Cross-Sectional

Other


There are 4 SNPs

SNPs


1 F64L

In this outcome, number of participants with each type of resulted mutation type (Val30Met, wild type TTR, Phe64Leu, Ser77Tyr, Thr60Ala or other than these) were reported. --- Val30Met --- --- Phe64Leu ---


2 S77Y

In this outcome, number of participants with each type of resulted mutation type (Val30Met, wild type TTR, Phe64Leu, Ser77Tyr, Thr60Ala or other than these) were reported. --- Val30Met --- --- Phe64Leu --- --- Ser77Tyr ---


3 T60A

In this outcome, number of participants with each type of resulted mutation type (Val30Met, wild type TTR, Phe64Leu, Ser77Tyr, Thr60Ala or other than these) were reported. --- Val30Met --- --- Phe64Leu --- --- Ser77Tyr --- --- Thr60Ala ---


4 V30M

In this outcome, number of participants with each type of resulted mutation type (Val30Met, wild type TTR, Phe64Leu, Ser77Tyr, Thr60Ala or other than these) were reported. --- Val30Met ---



HPO Nodes


HPO:
HP:0001638: Cardiomyopathy
Genes 716
NDUFS7 PEX5 PDGFRA LMNA TCAP TPM1 EPG5 SGCB DOLK GPC4 PCCB XK MLX CPT2 GPR101 VCL TAZ MAP2K2 YARS2 TWNK RRM2B SDHA MC2R TMPO BRAF PRKAG2 BSCL2 AHCY TNNC1 NEU1 XRCC4 IDUA VPS33A GABRD TRNL1 CAP2 MYO18B IDH2 NDUFA10 GYG1 VCL LAMC2 NDUFV2 SLC25A4 TNNI3K RNU4ATAC CHKB DES MYH7 JUP BAG3 PEX10 MYBPC3 HADHA TRNL1 CRYAB SLC2A10 LMNA RAF1 TMEM43 MYOT HADHA WFS1 MAP2K1 TACO1 HADHA MYH7 PPA2 ACTN2 HSD17B10 GPC4 PEX19 NDUFB11 MYLK2 COX10 SARDH NAGA TRNK MRPL3 ATP6 TMEM70 GMPPB ND1 DES MAP2K2 KLF1 POMT2 NDUFS1 CAV3 KRAS DPM3 HFE COX2 FASTKD2 PTPN11 ITPA ANK1 CDKN1C FKTN ACTA1 TK2 RYR1 BSCL2 RNASEH2A ATP5F1D SHOC2 SDHA NDUFS3 FHL1 ANO5 HNRNPA2B1 PARS2 PPCS NDUFA11 ND3 XRCC2 FOS TPM3 RBCK1 TNNT2 ELAC2 TRNQ ACTA1 COX6B1 NDUFB11 COL7A1 HRAS PALB2 NDUFB8 COX7B ABCC9 COX8A ND3 TGFB3 ACADS TMEM126B DSP LDB3 FANCE DES RMND1 HADHA PSEN2 NDUFS2 TTR NDUFS2 TRNS1 H19 ARSB LAMP2 SLC25A20 PTPN11 RAD51 ALMS1 RAF1 NDUFS2 TNNT2 FKTN TAZ POLG2 COQ4 NRAS RAF1 HNRNPA1 RAB3GAP2 SGCB ACTC1 SYNE1 MYH7 NF1 HACD1 MYL3 AGK POLG COX7B PEX7 FANCD2 SYNE2 SLC25A4 KCNJ8 GLA ANKRD11 FHL1 SYNE2 DSP TERT USP9X TPM2 LAMA3 NDUFA2 SDHA SDHB MRPS22 ND1 NAXD DMD FXN SPEG GNPTAB SHOC2 IDUA FKRP NDUFA12 NDUFAF4 BMP2 ND6 NNT COG7 ECHS1 GATAD1 FHL2 NDUFV2 LDB3 TOP3A ND2 SLC25A4 POMT1 ERCC4 HADHB PNPLA2 CSRP3 LAMA2 DLD MTFMT SUFU SCO2 VPS13A NEBL POMK FLNC RNF113A HMGCL MYH6 AGK TSFM MAP2K1 TNNI3 BRCA1 TRNS1 GATA4 MRPL44 FIG4 LAMA4 RFWD3 PCCA NDUFS2 PRKAG2 COX1 DTNA HPS1 DMD TNNT2 BRAF LMNA COL7A1 FXN LMNA NBAS TXNRD2 ND5 NDUFAF6 PEX14 ACADVL EMD ND4 WARS2 ANKS6 TMEM126A TREX1 GPC3 FKRP PKP2 ATAD3A NUP107 MEN1 LMNA CAV1 HADHB HGSNAT MMUT ELN PEX26 TGFB1 PMM2 FLNC H19-ICR NDUFA11 TWNK LDB3 PLN SLC19A3 SCN5A RAF1 FOXRED1 NEXN NDUFAF2 FANCC TPI1 HJV PET100 MAD2L2 SLC25A3 KBTBD13 ERCC2 NDUFB9 MMUT DOLK PPARG FOXRED1 NDUFS7 TRNV PLN PCCA TAPT1 COX14 SCN5A CSRP3 ACAD9 VCP KRAS RFC2 ERBB3 GTPBP3 ERCC3 GSN NDUFAF1 DSC2 LAMP2 TRNN NDUFV1 LMNA TXNRD2 PTPN11 MYL2 ND6 TRNT PET100 CPT1A FKTN ABCC9 XYLT1 HLA-B XYLT2 PEX3 COX15 DSG2 NDUFA10 DSG2 DPM3 SDHD TRNW TRNF JUP TPM2 OPA1 MICOS13 DNAJC19 NDUFA6 NDUFS1 PNPLA2 NAGA PHYH DNAJC19 PMM2 LMNA NDUFAF4 ACTA1 LAMA4 PRDM16 ND2 EYA4 MLYCD PPCS PEX6 PIGT CRYAB GNE NDUFAF1 MYBPC3 ALG1 SLC30A10 SKI NDUFAF3 TAZ TTN KCNAB2 ACADVL INSR SLC25A3 CPT2 BRAF AGPAT2 TNNI3 ENPP1 WFS1 CISD2 MYH7 COA8 SELENON POMT1 LIMK1 MRAP PRKAG2 SCO2 TBL2 PEX2 RIT1 MYSM1 UBE2T GJA5 USP8 ND4 LAMB3 TRNT1 TACO1 DMD RNASEH2B ACTN2 SPTB NDUFA9 TWNK CSRP3 FLAD1 AARS2 ATPAF2 EPG5 MTO1 SPTA1 FBXL4 RERE NDUFS4 SGCD TNNC1 LDB3 MAP3K20 JUP ABCC6 CPT2 GATA5 FAH NDUFS3 ACAD9 COX20 VCL ACAD8 GSN NDUFAF2 FANCL SDHA FKTN TWNK RRM2B GMPPB IFIH1 SOS1 SLC40A1 MYH7 FHL1 FOXRED1 PEX7 COX15 SURF1 TTN SELENON TRIP4 GMPPB DCAF8 KCNH1 NEK8 NDUFS6 TTN ACADL HADH NDUFAF3 POLG CLIP2 NDUFV1 BRIP1 SLC19A2 DSG2 TNNT2 KRAS BAG3 JUP GYS1 TNNI3 POMGNT1 IGF2 FANCF ANKRD1 COA6 ADCY5 TMEM126B LIAS EYA4 PCCB ACTC1 GNS ACTA1 HAMP C1QBP DSP NDUFB11 ATAD3A ADCY5 BRAF ADAR GTF2E2 TIMMDC1 STAR FKRP CRYAB LMNA TPM2 CRYAB MYOZ2 NDUFAF5 SGSH ACAD8 TRNK RNASEH1 AGL TTR IDUA NDUFS8 CPT2 SLC25A20 NEXN ABHD5 RMRP COA5 KCNQ1 PEX7 ITGA7 COQ2 NDUFS8 ND1 FANCA NDUFA13 TRNL1 POMT1 NDUFS4 MYH7 SLC4A1 TMEM43 GTF2H5 FANCM TARS1 MYH6 CLN3 POLG DLD AHCY TPM3 GBE1 SDHAF1 PSEN1 MYL2 CDH23 BAG3 RAF1 NDUFB10 NDUFAF5 SGCA KAT6B MYH6 POLG UBR1 PEX13 MPLKIP TNNI3 PSEN1 MYBPC3 MGME1 NEB PEX11B SDHA TPM1 RBM20 LTBP4 ALMS1 COA8 HBB BBS2 POMT2 AIP PDHA1 MIB1 DSP ALG1 BRCA2 CENPE NDUFS4 ND5 HAMP NDUFB11 MYPN TTPA POMT1 RAD51C MGME1 GTF2I EPB42 TRNW PEX1 PPP1CB COX3 MYPN RNU4ATAC BCS1L FTO RNASEH2C MYPN LMNA TFR2 GUSB TMEM70 NDUFA4 SLX4 TRNH ATP6V1A D2HGDH NEXN GATAD1 PSEN2 NUP107 HFE GLB1 SCO1 NDUFA2 ATP6 HCCS TNNC1 NEB NAGLU AIP TRNS2 HRAS PIGT SGCD FANCG FANCI TTN SAMHD1 NUBPL PGM1 RBM20 ABCC9 MMP1 TANGO2 MRPS14 KCNQ1OT1 CAVIN1 PLN PPARG FIG4 LMNA MIPEP ACTC1 BAZ1B FHL1 DES MYH7 IL12B LMNA PRDM16 NDUFV2 ABCC6 SLC22A5 RYR2 ATP5F1E FANCB NDUFS8 MAP2K1 SDHAF1 GPC3 HADH HJV NPPA TPM3 KLHL41 MYPN AIP BOLA3 TRNE GTPBP3 DMD HCCS TCAP LIPT1 VAC14 SLC25A4 LIMS2 PEX16 DSP NDUFB3 JPH2 VPS33A SURF1 CLPB TNNI3 MYOT TAF1A PRDM16 TPM1 MYH6 POLG NDUFA1 GTF2IRD1 PEX12 SDHD DMD AGPAT2 TRNK SMC1A PHYH